Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...